CClinicalTrials.gg
CompletedNCT05305053Updated Jun 12, 2024

Practice Variation in Preoperative Multidisciplinary Team Discussions

An observational study in Pre-operative, High-risk Patient and Frailty, sponsored by Rijnstate Hospital. Completed at 9 sites in Netherlands. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Rijnstate Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
225
Ages
16 Years to 100 Years
Sex
All
01

Study summary

Preoperative multidisciplinary team (MDT)discussions are recommended by national and international guidelines. However, no guidance is given on how to organise and execute an MDT discussion. The objective of this study is to describe the methods used for preoperative MDT discussion executed in the Netherlands.

Read the detailed description

Due to the increase in life expectancy and improved care for patients suffering from a chronic disease, the number of complex patients requiring surgery increases. Surgical treatment is often the optimal treatment to improve survival, but it is important for high-risk patients, to balance the potential benefits of treatment against the risk of potential permanent loss of functional capacity and quality of life. Multidisciplinary Team (MDT) meetings may be a sophisticated solution to discuss the harm-benefit ratio between different caregivers. There are currently no randomized studies comparing preoperative MDT meetings for high-risk non-cardiac surgery patients with no preoperative MDTs. In observational studies, the preoperative MDT altered medical treatment and management in more than 80% of patients, including 13-36% of patients who, after MDT, did not undergo the planned surgical procedure.(1, 2) The implementation of a preoperative MDT for frail patients scheduled for colorectal surgery was associated with a statistically nonsignificant reduction in severe postoperative complications from 33% to 22% of patients or up to 25% changes in care management.(1, 3) In a retrospective study Sroka found that for 36% of the discussed, high-risk cancer patients the case was risk prohibitive. The retrospective study by Vernooij et al. showed that only 27% of discussed patients received care as planned.(4) In cancer care, extensive experience exists with MDT meetings also known as tumor boards. The introduction of MDTs has impacted patient treatment in oncology. However, these tumor boards may be hindered by an excessive caseload and time pressure(5) which may limit a positive effect of MDT meetings on patient outcome.(6) A preoperative MDT may therefore complement these tumor boards since only the high-risk cases are selected for discussion and medical consultants are invited based specifically on the patients' comorbidities.

Several international guidelines have recommended MDT discussions for high-risk patients but they are not widely implemented yet. (7-9) Not executing preoperative MDT meetings may be a consequence of the fact that objective evidence for the value of the preoperative MDT meetings for high-risk, noncardiac patients is practically nonexistent. Also, no guidance exists on how best to organize an MDT meeting. Sroka proposes a protocol for the identification and multidisciplinary discussion of predefined high-risk patients.(2) In the current multicenter observational study in the Netherlands, the aim is to document how preoperative MDT meetings for high-risk non-cardiac surgery patients are executed. For the hospitals where MDT meetings are executed, considerable practice variation between hospitals may exist concerning performing and organizing MDT meetings. The practice variation may exist regarding patient selection, MDT meeting organization and attendance, MDT discussions, decisions made and, lastly, regarding nonsurgical management.

The first objective of this study is to describe the practice variation in executing preoperative MDT meetings in the presence of an anesthesiologist. The research question is: How much and what kind of variation exists in execution of preoperative MDT meetings for high-risk non-cardiac surgical patients. Secondary objectives are: what is the frequency of care management changes ordered by an MDT discussion; how do these changes affect outcome of the patients measured by the frequency of Serious adverse events; 30 day, 3 months and 12 months mortality postoperatively or post MDT discussion; calculated risks; differences in high-risk patient identification and the relation between calculated risks and outcome.

02

Conditions studied

  • Pre-operative
  • High-risk Patient
  • Frailty

Browse trials for

Keywords

  • high-risk;
  • preoperative risk prediction
  • perioperative mortality
  • Multidisciplinary Team meeting
03

In context

Frailty

1,200 studies on the registry are indexed under Frailty; 429 are open to participants now.

This study's enrollment of 225 is close to the median of 223 across 496 observational studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Rijnstate Hospital is the lead sponsor of 127 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All high risk noncardiac surgical patients selected for a preoperative MDT discussion.

Inclusion criteria

* All patients selected for a Multidisciplinary Team discussion

Exclusion criteria

Exclusion Criteria:

* No implicit consent given for scientific research

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
225 participants (actual)
Patient registry
No

Groups and cohorts

  • high-risk noncardiac surgery patients for preoperative Multidisciplinary Team (MDT) discussion

    observation of MDT in 11 hospitals

    Other: preoperative MDT discussion

Interventions

  • Otherpreoperative MDT discussion

    high-risk patients are subjected to an MDT discussion among care providers

06

What researchers measure

Primary outcomes

  1. Attendance of the MDT

    number of carers present at meeting

    Time frame: 1-4-2022 untill 1-10-2022

  2. Decisions made in MDT

    number of decisions made

    Time frame: 01-04-2022 untill 01-010-2022

  3. 12 months postoperative mortality or post MDT

    number of patients that died within 12 months postoperative or 12 months post MDT

    Time frame: 01-04-2022 untill 01-10-2024

Secondary outcomes

  1. 30 day postoperative mortality or post MDT

    number of patients that died within 30 days

    Time frame: 01-04-2022 untill 01-10-2022

  2. Serious adverse events at 12 months postoperative or post MDT

    number of serious adverse events per patient at 12 months postoperative or 12 months post MDT classified by the Clavien Dindo Classification

    Time frame: 01-04-2022 untill 01-10-2024

  3. Hospital admissions at 12 months postoperative or post MDT

    number of hospital admissions per patient at 12 months postoperative or 12 months post MDT

    Time frame: 01-04-2022 untill 01-10-2024

07

Study locations

9 sites
  • MC Leeuwarden
    Leeuwarden, Friesland, Netherlands
  • Rijnstate Hospital
    Arnhem, Gelderland 6800 TA, Netherlands
  • Gelderse Vallei
    Ede, Gelderland 6716RP, Netherlands
  • Catharina Ziekenhuis
    Eindhoven, Noord Brabant, Netherlands
  • Amsterdam University Medical Centre location VU
    Amsterdam, Zuid Holland 1081HV, Netherlands
  • LUMC
    Leiden, Zuid Holland, Netherlands
  • Maasstad Ziekenhuis
    Rotterdam, Zuid Holland 3079DZ, Netherlands
  • Franciscus Gasthuis
    Rotterdam, Zuid Holland, Netherlands
  • UMCU
    Utrecht, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05305053
Lead sponsor
Rijnstate Hospital
Responsible party
Jacqueline Vernooij (Principal investigator, Rijnstate Hospital) — Principal investigator
First posted
Mar 31, 2022
Start date
Apr 1, 2022
Primary completion
Jun 1, 2024
Completion
Jun 1, 2024
Last update
Jun 12, 2024

Study contacts

Jacqueline M Vernooij, MD
principal investigator · Rijnstate

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion